3 Houston health tech innovators to know this week

who's who

This week's roundup of Houston innovators includes Matthew Kuhn of Taurus Vascular, Tim Boire of VenoStent, and Howard Berman of Coya Therapeutics. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three health tech innovators celebrating milestones for each of their companies.

Matthew Kuhn, co-founder and CEO of Taurus Vascular

Taurus Vascular is one step closer to stopping abdominal aortic aneurysms for good. Photo courtesy of TNVC

A Houston biotech company has won the Texas A&M New Ventures Competition (TNVC). Taurus Vascular took home $30,000 for its first-place victory.

Taurus Vascular is working on a new solution to stopping abdominal aortic aneurysms (AAA) before they rupture and become potentially fatal. The company arose out of the TMC Innovation Biodesign Program. Fellows Matthew Kuhn and Melanie Lowther had a year to bring a company to fruition. The highly qualified team can boast of Kuhn’s more than 40 patents and Lowther’s former role as director of entrepreneurship and innovation at Texas Children’s Hospital.

The competition’s intense process included presenting to commercialization experts across several rounds. In fact, vetting takes four months and includes coaching to help competitors thrive in their pitches. Read more.

Tim Boire, CEO and co-founder of VenoStent

VenoStent has raised additional funding. Image courtesy of VenoStent

A clinical-stage Houston health tech company with a novel therapeutic device has raised venture capital funding and secured a grant from the National Institutes of Health.

VenoStent Inc., which is currently in clinical trials with its bioabsorbable perivascular wrap, announced the closing of a $20 million series A round co-led by Good Growth Capital and IAG Capital Partners. The two Charleston, South Carolina-based firms also led VenoStent's 2023 series A round that closed last year at $16 million.

Additionally, the company secured a $3.6 million Small Business Innovation Research (SBIR) Phase II Grant from NIH, which will help fund its multi-center, 200-patient, randomized controlled trial in the United States.

Tim Boire, VenoStent CEO and co-founder, describes 2024 so far as "a momentous year" so far for his company. Read more.

Howard Berman, CEO and co-founder of Coya Therapeutics

Coya Therapeutics announced an expanded research collaboration with the Houston Methodist Research Institute, as well as funding from the Johnson Center. Photo via LinkedIn

A clinical-stage Houston biotech company has expanded its collaboration with Houston Methodist Research Institute, or HMRI.

Coya Therapeutics is already sufficiently established to be publicly traded since late 2022, but there’s always room to grow. With the help of a new sponsored research agreement, Coya will work on multiple initiatives. Coya is led by co-founder and CEO Howard Berman, who was inspired by his father’s dementia diagnosis.

"I was interested in what I could do for my dad," Berman said on the Houston Innovators Podcast, explaining that he met with renowned Houston Methodist researcher and neurologist, Dr. Stanley Appel, who showed him that he was not only working on treatments that could help Berman’s now-deceased father, but that he’d been able to stop the progression of ALS. Read more.

From Your Site Articles
Taurus Vascular is one step closer to stopping abdominal aortic aneurysms for good. Photo courtesy of TNVC

Houston health tech startup scores $30,000 prize at annual pitch competition

big winner

A Houston biotech company has won the Texas A&M New Ventures Competition (TNVC). Taurus Vascular took home $30,000 for its first-place victory.

Taurus Vascular is working on a new solution to stopping abdominal aortic aneurysms (AAA) before they rupture and become potentially fatal. The company arose out of the TMC Innovation Biodesign Program. Fellows Matthew Kuhn and Melanie Lowther had a year to bring a company to fruition. The highly qualified team can boast of Kuhn’s more than 40 patents and Lowther’s former role as director of entrepreneurship and innovation at Texas Children’s Hospital.

The competition’s intense process included presenting to commercialization experts across several rounds. In fact, vetting takes four months and includes coaching to help competitors thrive in their pitches.

“As we celebrate the tenth year of the Texas A&M New Ventures Competition, we recognize the significant economic impact these startups have across Texas and their worldwide societal contributions,” says Chris Scotti, TNVC chair, in a news release. “Looking ahead, we are excited to continue fostering innovation and supporting science and engineering-based companies that drive progress and create lasting change.”

In its decade of competitions, TNVC has awarded almost $4 million prizes to startups. This year alone, 27 awards were distributed. Those included investment capital, consulting, legal and engineering services, and other types of support tailored to the winners’ needs.

“We are honored to have won first place at the Texas New Ventures Competition. Competing alongside so many outstanding companies and talented founders makes this recognition even more meaningful and reflects the dedication and hard work of our team at Taurus Vascular,” Kuhn says in a press release. “The financial support and increased visibility from this win will be pivotal for our growth, unlocking new opportunities and partnerships.

"This award strengthens our belief in our mission of reducing endoleak risks in endovascular aortic aneurysm repair and making a positive impact on patient care," he continues. "We are also grateful to Biotex for choosing us as a recipient for their sponsored prize and eagerly anticipate collaborating with them in the next phase of our technology’s development.”

Fewer than 20 percent of patients whose AAAs rupture survive. Kuhn told InnovationMap last year that he hopes to commercialize his technology by 2030. This competition brings patients closer to one day having far better odds when contending with a AAA.

This week's roundup of Houston innovators includes Erik Ibarra of Magnolia Fund, Matthew Kuhn of Taurus Vascular, and Libby Covington of The Craig Group. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from investment to biodesign — recently making headlines in Houston innovation.

Erik Ibarra, founder of Magnolia Fund

Erik Ibarra's latest venture is to give agency to residents in the neighborhood he grew up in. Photo courtesy

For years, Erik Ibarra has watched Houston's East End — La Segunda Barrio — evolve. Now, with tons of construction in the works, he's got a plan for a business that will tap into existing residents to give them ownership of their community.

Ibarra started Magnolia Fund, a mission-driven investment fund dedicated to enriching the East End community and preserving the neighborhood's culture and history. Ibarra, who has lived in the area the majority of his life, says on the Houston Innovators Podcast, that he's looking to turn residents into investors.

"Over the years, I've felt like there's so much development going on. But, the people from the neighborhood are very often just passive — they don't get a chance to benefit from or think about how they could participate in these new developments," Ibarra says. "The neighborhood is very close to my heart, and, about a year ago, I realized I wanted to do something about this." Read more.

Matthew Kuhn, co-founder of Taurus Vascular

A new innovation out of the Texas Medical Center's Biodesign Program is enhancing efficacy of a life-saving aortic aneurysm rupture procedure. Photo courtesy

As part of the current class of the TMC Innovation Biodesign Program, fellows Matthew Kuhn and his co-founder Melanie Lowther were tasked with creating a biomedical company in a year. The founders came up with Taurus Vascular, a medical device company that improves efficacy of abdominal aortic aneurysms treatment.

“It used to be if you had a AAA, you had a gnarly procedure,” Kuhn tells InnovationMap, which included a large incision across the abdomen. The standard treatment, endovascular aneurysm repair, or EVAR, eliminated that, but its problem is that it often results in endoleaks. As many as 20 percent of patients need another EVAR within five years.

Taurus Vascular’s technology improves on EVAR by placing a self-deploying stent to create a drainage pathway between the high-pressure aneurysm sac and a low-pressure nearby vein — mitigating the adverse impact of endoleaks that would otherwise cause the aneurysm to continue to grow. The simple solution will allow patients to live longer, healthier lives after their procedure. Read more.

Libby Covington, partner at The Craig Group

Houston expert shares how to use your data to improve your marketing efforts. Photo courtesy

Data can be hard to tap into when you're working within B2B sales, writes Libby Covington in a guest column for InnovationMap.

"When focusing on revenue growth in business to business companies, analyzing data to develop and optimize strategies is one of the biggest factors in sales and marketing success," she writes. "However, the process of evaluating B2B data differs significantly from that of B2C, or business to consumer. B2C analysis is often straightforward, focusing on consumer behavior and e-commerce transactions."

In her column, Covington shares her advice on navigating this process. Read more.

A new innovation out of the Texas Medical Center's Biodesign Program is enhancing efficacy of a life-saving aortic aneurysm rupture procedure. Photo via Getty Images

Houston biodesign innovators ready to spin out startup with life-saving vascular tech

heartbreak healers

Yes, you can die of a broken heart — although it's not in the hyperbolic way you might be thinking. Fewer than 20 percent of people who have an aortic aneurysm rupture survive the event. But aortic aneurysms can be treated if they’re caught before they burst. A new Houston company is devoted to a novel solution to helping patients with abdominal aortic aneurysms (AAA).

That company is Taurus Vascular. As part of the current class of the TMC Innovation Biodesign Program, fellows Matthew Kuhn and Melanie Lowther were tasked with creating a biomedical company in a year. The founders started their journey last August. At the end of this month, they'll be kicked out of the nest, Kuhn tells InnovationMap. Taurus is also in Rice University's 2023 cohort of OwlSpark, an ongoing summer program for startups founders from the Rice community.

Kuhn is a biomedical engineer who just scored his forty-fifth patent. The CEO says that he hit it off quickly with his co-founder and COO, Lowther, former director entrepreneurship and innovation at Texas Children’s Hospital.

Matthew Kuhn and Melanie Lowther co-founded Taurus Vascular as TMC Biodesign fellows. Photos via taurusvascular.com

Members of the Biodesign Program are paid a livable stipend to devote themselves fully to creating a pioneering company. Kuhn says that he became interested in finding a more effective way to heal AAAs during his four and a half years as a project leader at the Center for Device Innovation at the Texas Medical Center.

“It was ripe for innovation and we landed on a concept of some merit,” he says.

The current standard of care for AAAs is EVAR, or endovascular aneurysm repair, in which a surgeon inserts a stent to relieve pressure on the aneurysm.

“It used to be if you had a AAA, you had a gnarly procedure,” he says, which included a large incision across the abdomen. EVAR eliminated that, but its problem is that it often results in endoleaks. As many as 20 percent of patients need another EVAR within five years.

Taurus Vascular’s technology improves on EVAR by placing a self-deploying stent to create a drainage pathway between the high-pressure aneurysm sac and a low-pressure nearby vein — mitigating the adverse impact of endoleaks that would otherwise cause the aneurysm to continue to grow. The simple solution will allow patients to live longer, healthier lives after their procedure.

Kuhn says that being in Houston has been and will continue to be instrumental in his company’s success. Part of that, of course, is his relatively cosseted status as a founder in the Innovation Biodesign Program. But he says that the industry as a whole has become almost like a family.

“It feels very different from startup life for other industries where it feels competitive,” he explains. "You have to be a little crazy to start a medical device company and there’s a sense that we’re all in the same boat. People are so generous with their time to share resources. I feels like I have 100 co-founders."

Following the end of Taurus Vascular’s time in the program that helped conceived it, its founders will remain in the same building, continuing to work to support their technology. The next step is raising a seed round that will pay for the company’s chronic animal studies. Because Taurus Vascular is producing a Class III medical device, its approval process to get to market is the most stringent the FDA has.

The goal is to be commercial by 2030, says Kuhn. By then, Taurus Vascular will have healed many a heart.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda closes $7 million funding round

fresh funding

Houston-based digital advance care planning company Koda Health has closed an oversubscribed $7 million series A funding round.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

“This funding allows us to create more goals-of-care product lines, expand our national footprint, and bring goal-concordant care to millions more patients and families," Tatiana Fofanova, co-founder and CEO of Koda Health, said in the release.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, has seen major growth this year and said it now supports more than 1 million patients nationwide. The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April and with Epic Systems in July. Users of Epic's popular Mychart system and Guidehealth's clinically integrated networks can now document and share their care preferences, goals and advance directives for health systems using Koda Health's platform. It also has partnerships with Cigna, Privia and Memorial Hermann.

The company shared that the recent series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space.

“Koda is the only company combining technology and service to deliver comprehensive solutions that help health plans, providers, and health systems scale goals-aligned care. With satisfied customers expanding their partnerships and policy shifts reinforcing the need for patient-centered care that also contains costs, we couldn’t be more excited to support the Koda team and their vision,” Sean Glass, managing partner at Evidenced, said in the release.

According to the company, a recent peer-reviewed study with Houston Methodist ACO showed that the platform can have a major impact on palliative care results and costs. The findings showed:

  • 79 percent reduction in terminal hospitalizations
  • 20 percent decrease in inpatient length of stay
  • 51 percent increase in hospice use among decedents
  • Nearly $9,000 in average savings per patient

“Patients long for clarity, families deserve peace of mind, and providers demand ease of use,” Dr. Desh Mohan, chief medical officer of Koda Health, added in the release. “At Koda, we make it possible to deliver all three — transforming Advance Care Planning into a compassionate, ongoing dialogue that honors patients and supports families every step of the way.”

Koda Health also closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. Read more here.

TXSE Group wins SEC approval for Texas Stock Exchange to start in 2026

Trading in Texas

The U.S. Securities and Exchange Commission has given the go-ahead to the Dallas-based Texas Stock Exchange to operate as a national securities exchange, clearing the way for the TXSE to begin trading stocks and exchange-traded products by early 2026.

TXSE is the first fully integrated national securities exchange to receive SEC approval in decades. A release calls it "a milestone decision" that restores competition in America's public markets.

The organization has already laid the groundwork with an exchange platform utilizing the appropriate hardware and software that will function in an evolving trading and regulatory environment.

TXSE, which opened its headquarters in Dallas in spring 2025, will launch trading as well as ETP and corporate listings for companies that meet their standards and are fully transparent. Their goal is to compete with the NYSE and NASDAQ by building up a large roster of newly listed companies.

"Today's approval marks a pivotal moment in our effort to build a world-class exchange rooted in alignment, transparency, and partnership with issuers and investors," says TXSX founder and CEO James H Lee. "Real competition for corporate listings in the United States has finally arrived."

According to the release, TXSE's mission is to reverse a decades-long decline in the number of U.S. public companies by reducing the burden of going and staying public while maintaining high quantitative standards in the industry.

They've already pushed for legislative and legal reforms to strengthen Texas' pro-business environment and establish the state as the premier jurisdiction for corporate headquarters, listings, and exchange operators — working alongside Texas leadership to advocate on behalf of issuers and investors to reform policy.

"As the one and only national securities exchange built and headquartered in Texas, we are proud to have been the catalyst for the development of capital markets in our great state," Lee says.

TXSE's founding investors include financial institutions, retail, and institutional investment organizations, including BlackRock, Citadel Securities, and Charles Schwab, as well as major liquidity providers and corporate executives from across the U.S.

TXSE will be one of three exchanges to join Texas' so-called economic hub Y’all Street, along with the New York Stock Exchange and NASDAQ.

---

This article originally appeared on CultureMap.com.

10+ can't-miss Houston business and innovation events for October

where to be

Editor's note: Houston's October calendar is packed with informative and impactful events—plus a few fun ones, too. From the fourth annual Tejano Tech Summit to the first-ever Ion Family Tech Festival, here's what not to miss and how to register. Please note: this article may be updated to include additional event listings.

Oct. 3 — Houston Methodist Joy in Medicine Initiative Symposium

The Houston Methodist Joy in Medicine Initiative Symposium will explore the power of connection in enhancing professional fulfillment for clinicians and healthcare teams, this year under the theme “The Power of We.” Hear from Dr. Shlomit Schall, Houston Methodist Physician Organization president and CEO and chief physician executive, and Dr. J. Bryan Sexton, director of the Duke Center for Advancement and Well-being Science. Stick around for a networking happy hour.

This event is Friday, Oct. 3, from 8:30 a.m.-4:30 p.m. at the InterContinental Houston. Find more information here.

Oct. 6-10 — Surgical Technology & Robotic Surgery Summit (STaRS)

Surgeons, engineers, researchers and innovators can explore the latest advancements in surgical robotics, imaging and AI-integrated technologies at this year’s Surgical Technology & Robotic Surgery Summit. They can also take in the inaugural Surgical Technology & Robotic Surgery Innovator Competition. The summit will feature live demonstrations, interactive panels and cutting-edge research.

This event begins Monday, Oct. 6, at MITIE at The Bookout Center. Find more information here.

Oct. 7 — SUPERGirlsInSTEM Summit: The Intersection of AI & Workforce

The SUPERGirls SHINE Foundation presents its SUPERGirlsInSTEM Summit, where attendees can take part in open discussions, networking and workshops while learning about AI skills that can advance college studies and entry into the workforce.

This event is Tuesday, Oct. 7, from 9 a.m.-1 p.m. at the Ion. Find more information here.

Oct. 7 — Future of Health Care: Thought Leader Series

Hear from Rice University President Reginald DesRoches, and Kristen Doyle, CEO of the Cancer Prevention and Research Institute of Texas, at the Greater Houston Partnership’s Future of Health Care: Thought Leader Series. The expert panel will discuss key topics, including the proposed Dementia Prevention and Research Institute of Texas (DPRIT), Rice's Momentous strategic plan and "critical role of public health systems and cross-sector partnerships in advancing access, equity, and workforce readiness."

This event is Tuesday, Oct. 7, from 9-10:15 a.m. at The Partnership Tower. Find more information here.

Oct 7-9 — Tejano Tech Summit Week

LSA Global will present its fourth annual Tejano Tech Summit Week. The week will feature happy hours, networking opportunities and a founders dinner, along with talks from Mariela Salas, co-founder and partner of Alma Fund; Latina in Tech Houston, Blue People, The Magnolia Fund and others.

This event starts on Tuesday, Oct. 7, with most events taking place at the Ion. Find more information here.

Oct. 8 — Digital Health Institute Launch event

Celebrate the launch of the Houston Methodist-Rice Digital Health Institute, which aims to translate “innovative ideas into scalable solutions” with a focus on engineering, digital health and artificial intelligence. The event will feature presentations from Houston Methodist clinical researchers and Rice University faculty, a startup and industry panel and a venture capital investment panel.

This event is Wednesday, Oct. 8, from 8 a.m.-6:30 p.m. at Rice University's Duncan Hall - McMurtry Hall. Find more information here.

Oct. 8 — Founders Live Houston

Founders Live Houston returns this month with its happy hour pitch event. The global competition will select five Texas founders to present 99-second pitches and participate in a four-minute audience Q&A. Voters decide the winner.

This event is Thursday, Oct. 8, from 6-8 p.m. at the Ion. Find more information here.

Oct. 14 — NASA Stories at the Ion

Dina Contella, deputy manager of NASA’s International Space Station Program, will speak at this month's NASA Stories event. Contella will share insights from her career overseeing International Space Station operations, shaping Artemis missions and guiding real-time decisions in Mission Control.

This event is Tuesday, Oct. 14, from 8:30-10:30 a.m. at the Ion. Find more information here.

Oct. 16 — Impact Hub Houston Celebrates 7 Years in Community + Open Project Night

Celebrate seven years of Impact Hub Houston with a hands-on learning experience focused on hosting. The organization will share the tools, practices and hosting frameworks that have helped it build community and support local changemakers since it launched in 2018. Afterward, participate in Impact Hub's signature Open Project Night, where developers can come together to work on solutions for some of Houston’s most pressing issues.

These events are on Thursday, Oct. 16, at the Ion. The anniversary party is from 2-5 p.m. and Open Project Night begins at 5:30 p.m. Find more information here and here.

Oct. 16 — Future of Global Energy presented by Shell

Industry leaders, academia, and government will "explore the forces shaping the future of energy" at the Greater Houston Partnership's fifth annual Future of Global Energy Conference. Andy Karsner, chief strategist for energy and innovation at X, Alphabet’s Moonshot Factory, and a former U.S. Assistant Secretary of Energy, will present the keynote address. Speakers from companies Fervo Energy, S&P Global, Bechtel and others will also be featured on panels and in fireside chats. The event will culminate in Houston's first National Labs Day, where attendees can engage with leaders and technology specialists from Argonne National Laboratory, Brookhaven National Laboratory and other institutions.

This event is Thursday, Oct. 16, from 9 a.m.-3:30 p.m. Find more information here.

Oct. 23 — NASA Tech Talks

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, Oct. 23, from 6-7 p.m. at the Ion. Find more information here.

Oct. 25 — Ion Family Tech Festival

The Ion and partners will present the first-ever Ion Family Tech Fest this month, where families can participate in hands-on STEAM experiences.

This event is Saturday, Oct. 25, from 10 a.m.-1 p.m. at the Ion. Find more information here.

View All Listings